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Introduction
Although significant advances in respiratory care have been made in neonatal medicine,
bronchopulmonary dysplasia (BPD) remains the most common serious pulmonary morbidity
in premature infants. Premature infants with BPD have a longer initial hospitalization than
their peers without BPD1 and BPD remains a substantial lifelong burden. The costs of the
disorder are both social and economic and are measured in impaired childhood health and
quality of life, family stress and economic hardship, and increased healthcare costs.2–4
Over the last 40 years the definition, the disease, and the risk factors for BPD have
changed.5,6 BPD, as it was initially described by Northway in the 1960’s, was based on
clinical and radiographic evidence of pulmonary disease in moderately to late premature
infants with a history of respiratory distress syndrome.7 The respiratory management of
these infants included exposure to prolonged mechanical ventilation and oxygen exposure.
On histological samples, the characteristic areas of hyperinflation alternating with areas of
focal collapse were often noted, as well as hyperplasia of the bronchial epithelium.8
Radiography of these infants showed areas of heterogeneity throughout the lung fields and
coarse scattered opacities in the most severely affected of infants.9
The ‘classical’ BPD described by Northway has been replaced by a milder form of the
disease. There is reason to believe that risk factors associated with the “new” BPD,
compared to historical risk factors, may be distinct. This “new” BPD occurs in less mature
infants exposed to antenatal steroids, who are often treated with exogenous surfactant
therapy. They spend fewer days on positive pressure ventilation and have less exposure to
supplemental oxygen. Animal studies suggest that the histology of “new” BPD shows more
diffuse disease, fewer areas of hyperinflation, a reduction in alveoli and capillaries, but little
fibrosis.10,11
The incidence of BPD varies widely between centers even after adjusting for potential risk
factors. Data from 2010 from the Vermont Oxford Network shows the rates of BPD vary
from 12% to 32% among infants born less than 32 weeks gestation. Although there have
been multiple trials aimed at reducing the incidence of BPD, it seems that the incidence is
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stagnant, or even increasing. The rising absolute number of infants with BPD might be due
to the improvement in the survival of extremely low gestational age infants, the population
most likely to carry this diagnosis.5,12,13 Compared with the pathology described by
Northway, the most common type of BPD today may be a less severe form of the disease.
This chapter will review the definitions of BPD, and the predictors of BPD by time period
(before, at, and after birth). In addition, several of the estimators that are available to
quantify the risk of BPD, and explain how this might affect clinicians, families, and
researchers are reviewed.
Defining BPD
The definition of BPD most often uses receipt of oxygen therapy or positive pressure for a
duration of time (usually in days) or on a specific day (e.g. postnatal day 28 or at
postmenstrual age 36 weeks). The original definition was based on receipt of oxygen at 28
days of age. However, this definition does not take into account the various developmental
considerations of infants born across the spectrum of susceptible gestational ages. Thus,
attempts have been made to improve the definition through a corrected age “cutpoint”, most
commonly the need for supplemental oxygen therapy at 36 weeks PMA. The NICHD
divided the definition further using a severity scale. Since oxygen saturation targets vary
from center to center, a “physiologic definition” has been proposed as well. These
definitions are reviewed in more detail below.
A workshop to clarify the definition of BPD was held by the National Institute of Child
Health and Human Development in June 2000 with the goal to distinguish BPD from
chronic lung disease (CLD), a condition that was felt to represent a group of heterogeneous
diseases occurring later in life.14 This workshop proposed a severity-based definition that
classified BPD as mild, moderate or severe based on either postnatal age or PMA (Table 1).
Mild BPD was defined as a need for supplemental oxygen (O2) throughout the first 28 days
but not at 36 weeks PMA or at discharge; moderate BPD as a requirement for O2 throughout
the first 28 days plus treatment with <30% O2 at 36 weeks PMA; severe BPD as a
requirement for O2 throughout the first 28 days plus ≥ 30% O2 and/or positive pressure at 36
weeks PMA. Ehrenkranz et al15 validated the NICHD severity-based definition of BPD by
comparing it to the more traditional definitions of BPD such as supplemental oxygen at 28
days and at 36 weeks PMA. The consensus NICHD severity-based scale better identified
infants who are at most risk for poor pulmonary outcomes as well as neurodevelopment
impairment than the traditional definitions.15
The physiologic definition of BPD was developed by Walsh, et al 16 and defines BPD as a
failure to maintain a saturation value > 90% when challenged with 21% oxygen at 36 weeks
PMA. Unit-specific rates of BPD using the physiologic-definition were compared to rates of
BPD using the traditional definition of BPD (oxygen need at 36 weeks PMA) for premature
infants weighing 501–1249 grams. The physiologic definition reduced the between center
variability in the diagnosis of BPD and reduced the diagnosis as much as 10% at individual
centers. The physiologic definition has also been validated and shown to be independently
predictive of cognitive impairment in infants with BPD. 17 The physiologic definition is
used by the NICHD Neonatal Research Network centers throughout the United States.
Regardless of which definition of BPD one uses, a period of time is required before the
definition is made. This makes identifying therapies for premature infants at risk of BPD
challenging. An infant born at 23-weeks gestation who needs mechanical ventilation at 34
weeks postmenstrual age is likely to develop BPD, as defined as oxygen therapy at 36
weeks. That infant may benefit from strategies that improve short-term outcomes, but which
do not reduce the incidence of BPD. For example, in a Cochrane Systematic Review,
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Stewart et al. found the use of diuretics may transiently improve oxygenation and pulmonary
function, but did not reduce the development of BPD (RR 0.80 (95% CI: 0.18, 3.54).18
Recently, a prototype “Proxy Reported Pulmonary Outcome Score (PRPOS) has been
developed to define nuances in pulmonary function as reported by caregivers. The PRPOS
consists of 26 observations that can be made by a nurse before, during and after providing
routine care and feeding.19 The goal is to make assessments about functional domains of
infants that will help to discriminate between infants with none, mild, moderate and severe
pulmonary dysfunction. This novel approach might allow testing of therapies (such as
diuretics) aimed at improving pulmonary outcomes that do not require waiting for the
development of an outcome several days or weeks later.
Understanding and interpreting the predictors of BPD?
Predictors of disease are more commonly known as risk factors. In epidemiologic studies,
risk is most often used synonymously with probability of disease occurrence, however it
may represent a wide variety of statistical measures that include incidence, prevalence, rate
or odds. A risk factor often implies an increase in the outcome of interest with exposure,
although risk measures may also represent protective effects.20
In many studies, risks are often compared through relative measures – risk ratio, odds ratio
or rate ratio.21 Relative measures are helpful for identifying risk factors, but can be
misleading when not accompanied by absolute measures such as the risk difference. For
example a relative risk of 2.0 indicates that the exposed group is twice as likely to develop
the disease as the unexposed group. However, twice as likely may represent an absolute
change in risk from 0.2 (20%) to 0.1 (10%; risk difference of 0.1 or 10%) or may represent
an absolute change in risk from 0.002 (0.2%) to 0.001 (0.1%; risk difference of 0.001 or
0.1%). This is important because small changes in absolute risk differences might not be as
amenable to change as a large risk difference.
Attributable risk proportion (ARP), also known as the etiologic fraction, represents the
proportion of the incidence of disease among exposed persons that is due to the exposure.
The ARP is often useful when identifying risk factors in diseases such as BPD that are
multi-factorial. As with all risk measures, however, caution should be used when inferring
causality.22 Most diseases such as BPD have many component causes, some of which
remain either unknown or immeasurable. These component causes can occur at different
times and the sequence of their occurrence may be important in the development of the
disease. In addition, risk measures cannot distinguish a necessary cause from a component
cause. Removal of a single component cause can reduce disease burden, but removal of a
necessary cause may prevent the disease entirely.23 Several studies have demonstrated that
the retrospective examination of risk factors for BPD alone is difficult given the interrelation
of true risk factors, the difficulty in distinguishing temporal relationships and confounding
factors.24–26
Traditionally, researchers identified risk factors for BPD by categorizing premature infants
as having or not having BPD, using one of the definitions noted above, and then
retrospectively examining all factors that influenced risk up to the time of diagnosis. As a
result, each study has reached different conclusions regarding the risk factors for the
development of BPD. In addition, most used some type of multivariate modeling in an
attempt to adjust for potential confounders and effect modifiers (e.g. by adjusting for
gestational age).
For examples, in a study by Rojas et al27 risk factors for BPD in ventilator-supported
preterm infants weighing between 500 and 1000 g included low birth weight, presence of a
patent ductus arteriosus (PDA) and sepsis. Of these infants, 37% had a diagnosis of BPD as
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defined as oxygen therapy at 28 days. In contrast Marshall et al24 defined risk factors for
BPD as nosocomial infection, magnitude of fluid intake on day 2, PDA and need for
ventilation at 48 hours of life. Of the 1244 infants between 500–1500 g included in the study
26% developed CLD, defined as dependency on supplemental oxygen at 36 weeks
postmenstrual age. In a secondary analysis of the Neonatal Research Network Glutamine
trial, the risk factors for infants who died or developed BPD (defined as oxygen therapy at
36 weeks PMA) were lower birth weight and gestational age, male sex, lower 1 and 5-
minute Apgar Scores, higher oxygen requirement at 24 hours of age, longer duration of
assisted ventilation, use of postnatal steroids, severe intraventricular hemorrhage,
necrotizing enterocolitis, patent ductus arteriosus, and late onset sepsis.25 In preterm infants
with respiratory failure enrolled in the Neonatal Research Network inhaled nitric oxide trial,
the authors found that the risk of death or BPD was associated with lower birth weight,
higher oxygen requirement, male gender, additional surfactant doses, higher oxygenation
index and outborn status.26 These examples demonstrate that in multifactorial diseases, such
as BPD, multiple definitions as well as confounding in retrospective studies can distort the
exposure-outcome relationship.
Risk factors before birth
Antenatal Steroids
Antenatal steroids are associated with a decrease in severity of respiratory distress syndrome
and neonatal mortality.28,29 As a result, antenatal steroids were initially believed to decrease
the risk of BPD.30 In a study by Van Marter et al. using multivariate analysis, the
independent effect of antenatal steroids on the risk of BPD was examined. They found that
treatment with either a partial or full course of antenatal steroids did not convey any
additional benefit in reducing the likelihood of BPD after adjustment for other important
confounders such as gestational age, infection and respiratory management strategies (OR
0.98 95% CI: 0.66, 1.5). In a Cochrane analysis that included 818 infants from 6 studies, the
risk of BPD (defined as oxygen at 36 weeks PMA) was not significantly different between
infants who were exposed to antenatal steroids as compared to controls (RR 0.86, 95% CI:
0.61, 1.22). Overall these studies suggest that antenatal steroid exposure does not modify the
risk of BPD; however, this may be due to an increase in survival of the most immature
antenatal steroid-exposed infants.
Chorioamnionitis
Chorioamnionitis is one of the leading causes of very preterm delivery. The association
between chorioamnionitis and BPD is difficult to assess as the diagnosis has several
definitions. A clinical diagnosis of chorioamnionitis is commonly made based on maternal
symptoms and is subject to significant variability between providers. Furthermore, clinical
chorioamnionitis may only reflect acute inflammatory changes. Histologic evidence of
chorioamnionitis is the ‘gold standard’ and may reflect chronic infection but placental
pathology is not always available. Antenatal inflammation, such as chorioamnionitis, has
been associated with an increased rate of lung maturation.31 In a retrospective study by
Dempsey et al of 392 infants born at less than 30 weeks PMA, histologic chorioamnionitis
was associated with a higher incidence of premature deliveries and an increased risk of
sepsis.32 However, chorioamnionitis was also associated with a significant decrease in the
incidence of RDS (OR 0.43, p-value=0.001), a finding that has been repeatedly
demonstrated in multiple other studies.
The presence of chorioamnionitis is also associated with a disturbance in the normal lung
maturation and growth that may have an effect on the development of BPD.33–35 A recent
meta-analysis suggested that even when adjusted for other confounding factors there still
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remains an association between chorioamnionitis and an increased risk for BPD.36 However,
other studies aimed at identifying predictive factors for the development of BPD using a
histologic diagnosis suggest that there may be no true association with
chorioamnionitis.37,38
Fetal Growth Restriction
Fetal growth restriction, defined as a birth weight less than 1 standard deviation below the
median, is associated with an increased risk of BPD among premature infants. In a study by
Bose et al, characteristics and potential risk factors for BPD were evaluated among 1241
infants enrolled in the ELGAN study.37 The authors examined the role of prenatal factors,
such as preeclampsia and fetal indications for delivery, the microbiology and histology of
the placenta and neonatal characteristics including fetal growth restriction (FGR). Among
these infants, FGR was highly predictive of the development of BPD in all gestational ages
except the lowest (23–24 weeks), after adjustment. The investigators speculated that the
biologic mechanisms leading to FGR also lead to vulnerability of the developing lung,
rendering infants with FGR at higher risk for the development of BPD.
Risk factors at birth
Infant demographics: gestational age, birth weight, and sex
Extreme prematurity and extremely-low-birth-weight have been well established as risk
factors for BPD. Gestational age and birth weight are inversely proportional to the incidence
of BPD, as well as the severity of the disease. Among infants meeting the physiological
definition of BPD at 36 wk postmenstrual age (PMA), 95% are very-low-birth-weight
(VLBW).16 In the NICHD network,, the incidence of BPD at 23 weeks PMA (as defined as
oxygen at 36 weeks PMA) was 73% with 56% of infants having severe BPD. In comparison,
at 28 weeks PMA the incidence of BPD was 23% with only 8% of infants with severe
BPD.39 Male infants have a higher risk of developing BPD as compared to females.27,37,40
Risk factors after birth
Respiratory patterns
Describing the early respiratory patterns of ELGANs may provide insight into early risk
factors for BPD. Among ELGANs, three distinct patterns of lung disease typically emerge in
the first two weeks of life.41–45 The first pattern includes infants with relatively little lung
disease, who progressively recover. The second group of infants experience early persistent
pulmonary dysfunction (EPPD) and require significant and prolonged respiratory support
from birth. The third group experiences an initial improvement in their lung disease in the
first week of life, followed by a respiratory decompensation that often requires mechanical
ventilation and an increase in supplemental oxygen. This group is described as having
pulmonary deterioration (PD).
Almost half of infants who have PD develop BPD, which makes PD an important early
marker.46 The characteristics and exposure history of infants from the ELGAN study were
evaluated for associations with PD. Of the 1340 infants who were enrolled ~40% developed
pulmonary deterioration. Risk factors that may contribute to PD include late surfactant
deficiency47, sepsis, and PDA. The authors found that the most important markers of PD
were lower gestational age, lower birth weight, increased severity of illness (as defined as
neonatal acute physiology II score) and need for higher levels of respiratory support. Other
factors previously associated with PD, including male sex, multiple pregnancy, cesarean
section, antenatal steroids and infection were not statistically significant in multivariate
regression models.41,44 Among infants who had rapid resolution of their respiratory disease,
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17% (n=249) developed BPD (defined as supplemental oxygen at 36 weeks) compared to
51% (n=484) in infants with PD and 67% (n=576) among infants with EPPD. (Figure 1)
Mechanical ventilation
Mechanical ventilation is life saving for premature infants with respiratory failure. However,
mechanical ventilation uses positive pressure that produces ventilator initiated lung
injury.48,49 The development of surfactant therapy led to many extremely premature infants
receiving obligatory mechanical ventilation following surfactant replacement therapy.
However, reports emerged about substantial differences in BPD rates; infants born in centers
that used mechanical ventilation more frequently had a higher risk of BPD.50,51 For
example, the risk of BPD ranges from <10% to >40% among the Neonatal Research
Network centers in infants <1250 grams birth weight. 52 This variation is not explained by
differences in birth weight, gestational age, race, frequency of prenatal steroid use, or
incidence of respiratory distress syndrome.
Avoidance of mechanical ventilation might decrease the risk of lung injury and BPD, and
might explain some of the center-to-center differences in BPD rates.51 Mechanical
ventilation often begins shortly after birth; therefore delivery room management strategies
might influence the risk of BPD. 53,54 A full review of delivery room management and BPD
is presented in another chapter in this volume. The use of nasal continuous positive airway
pressure (CPAP) appears to be a successful strategy for avoiding the need for mechanical
ventilation in some infants, with the presumptive benefit of decreasing the risk of BPD.55
Postnatal steroids
The use of corticosteroids for the prevention or treatment of BPD has been examined in
numerous clinical trials. Two Cochrane reviews provide information about the effect of
treatment with systemic steroids on the incidence of CLD. Early treatment was defined as
beginning before postnatal day eight56; late treatment was defined as beginning after seven
days of postnatal age.57 Twelve trials examined the neurodevelopmental impact of early
corticosteroids and demonstrated an increase in the risk of cerebral palsy (RR 1.45, 95% CI
1.06, 1.98), with impairment of motor function a risk associated with early treatment.
Benefits of late treatment included decreased risks of BPD at both 28 days and at 36 weeks
PMA (RR 0.72, 95% CI 0.61, 0.85) and death or CLD at 28 days and at 36 weeks PMA (RR
0.72, 95% CI 0.63, 0.82). There was an increased risk of abnormal neurological
examination, but not an increase in neurosensory impairment or cerebral palsy.
The Dexamethasone: A Randomized Trial (DART) study identified patients at high risk for
BPD based on gestational age or birth weight (<28 weeks PMA or <1000g) and the need for
mechanical ventilation after postnatal day 7.58 Study infants were randomized to
dexamethasone or placebo. 60% of those who received dexamethasone (21 of 35) were
extubated by the 10th day of treatment as compared to 12% (4 of 34) in the placebo group.
Rates of mortality before follow-up, major disability, cerebral palsy, or the combined
outcomes of death or cerebral palsy were not substantially different between groups.
Furthermore, the incidence of BPD was 85% in the dexamethasone group and 91% in the
placebo group.59
For infants at high risk of developing BPD, corticosteroids might reduce the risk of BPD and
CP. In a meta-regression analysis, Doyle et al60 reviewed the results of available
randomized, controlled trials of postnatal corticosteroids and determined the risk of BPD
and cerebral palsy (CP) in the control groups. They found that the risk of CP increased with
the use of corticosteroids, however there was significant effect measure modification among
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the groups with BPD. As the risk of BPD increased (>65%), postnatal steroids reduced the
risk of death or CP.
Patent ductus arteriosus
The role of the patent ductus arteriosus (PDA) in the development of BPD in preterm infants
remains controversial. The presence of a PDA has been associated with the need for
prolonged mechanical ventilation, increased mortality and a higher risk of BPD.61,62
However, the relationship between PDA and BPD is often distorted by confounding factors
such as gestational age and illness severity and might not be causal.
In a randomized clinical trial by Schmidt et al (Trial of Indomethacin Prophylaxis in
Preterms (TIPP)), infants who received indomethacin prophylaxis had a decreased incidence
of PDA (21% vs 49%, p-value <0.05), however the incidence of BPD was similar between
groups (45% vs 43%, p-value 0.41).63 Indomethacin prophylaxis in this cohort increased the
supplemental oxygen use from day 3 to day 7, decreased urine output during the first 4 days
of life, and reduced weight loss by the end of the first week of life. Among infants who did
not develop a PDA following prophylactic indomethacin, treatment was associated with a
higher incidence of BPD (43% vs 30% p-value 0.015). These finding suggest that the early
side effects of indomethacin may contribute to the increased risk of BPD in the treatment
group.
Even when non-pharmacologic therapies are used to close the PDA the risk for BPD is
increased among treated infants. In a randomized trial of prophylactic PDA ligation among
infants weighing less than 1000 g, Clyman et al. found an increased incidence of BPD
(defined as supplemental oxygen at 36 weeks) and need for mechanical ventilation at 36
weeks among infants who underwent surgical ligation within 24 hours of birth.64 In
addition, the development of BPD in the control group was confined to infants who
ultimately needed surgical ligation (after 24 hours). They concluded that closure of the PDA
via surgical ligation increases the risk of BPD.
Prior studies to assess the role of ductal closure in the prevention of morbidities such as
BPD have had small sample sizes. Meta-analysis has consistently shown no decrease in the
risk of BPD with closure of the PDA.65–67 In a recent systematic review, Benitz reviewed all
available randomized controlled trials to create a pooled point estimate for the associations
between PDA closure and multiple morbidities. The pooled estimate showed a strong effect
of ductal closure with pharmacologic therapies (OR 0.23, 95% CI 0.20, 0.26), however a
non-significant effect on the incidence of BPD and BPD or death.68 It is likely that the
presence of a PDA is a marker for an increased risk of BPD.69 However, the large rate of
crossover and the design of these studies makes it challenging to assess the risks and
benefits of strategies designed to close the PDA.
Supplemental oxygen
For most infants, exposure to supplemental oxygen often begins in the delivery room. In a
Cochrane meta-analysis of studies comparing resuscitation with 100% oxygen to
resuscitation with room air in term and near term infants, resuscitation performed with room
air resulted in lower mortality than in those resuscitated with 100% oxygen (RR=0.71]).70
However, among preterm infants the role of supplemental oxygen therapy in the delivery
room is less clear. In a RCT of room air versus oxygen administration for the delivery room
resuscitation of preterm infants less than 32 weeks gestation (ROAR study), there was no
difference in the outcomes of BPD or death among infants treated with either room air,
titrated oxygen therapy or those who received static 100% oxygen.71 Although the use of
oxygen for preterm infants in the delivery room does not appear to influence the
Trembath and Laughon Page 7













development of BPD, it would still appear prudent to limit the use of supplemental oxygen
when possible.
Supplemental oxygen has been implicated as a potential toxin for the developing lung and
brain.72 Infants who require high amounts of oxygen may represent a more ill group of
infants for whom gas exchange is already impaired at the alveolar level; however, oxygen
can also produce oxidative injury to capillary, endothelial and alveolar membranes. Prior
studies have indicated that high levels of oxygen exposure result in increased
polymorphonuclear cell migration, increased proteolysis and elevated levels of
inflammatory cytokines.73,74 Yet, oxygen therapy is often necessary in premature infants in
order to prevent hypoxemia and oxygen may be important for cell growth and development.
In the Benefits Of Oxygen Saturation Targeting trial (BOOST-I), infants <30 weeks who
were randomized to higher oxygen saturations (95–98%) as compared to standard oxygen
saturations (92–94%) at 32 weeks corrected gestation, remained on oxygen therapy at 36
weeks corrected gestation more often (OR 1.40: 95% CI 1.15, 1.70). However, there was no
difference in the growth or development at 12 months between the two groups.75
The need for supplemental oxygen therapy can be a marker of severe illness and is therefore
associated with an increased risk of BPD. In the SUPPORT trial, one arm of the study
examined the effect of target ranges of oxygen saturations in extremely preterm infants.
Infants who were randomized to lower oxygen saturations (85–89%) as compared to infants
who were randomized to higher oxygen saturations (91–95%) had similar rates of BPD
among survivors 48.5 % vs 54.2% (RR 0.91 (0.83–1.01)).76 This would suggest that the role
of oxygen in the development of BPD for preterm infants is linked to the severity of illness
as compared to direct oxygen toxicity. Furthermore, the SUPPORT trial reported an increase
in mortality in the lower oxygen saturation group.
Vitamin A
Vitamin A is involved in multiple activities at the cellular level including regulating gene
transcription, signaling in embryonic development and as a potent antioxidant. These
functions are likely impaired in premature infants who also exhibit vitamin A deficiency.
Treatment with vitamin A replacement therapy decreases the risk of BPD or death by 36
weeks PMA in infants <1000g who remain on respiratory support at 24 hours of life (RR
0.89 [0.80, 0.99]).77 The supplementation was noted to increase serum vitamin A levels
without increasing the risk of toxicity. The use of Vitamin A in very low birth weight infants
has been hampered recently due to national shortages and lack of availability at many
centers.78
Caffeine
The use of caffeine for the treatment of apnea of prematurity has been demonstrated to
decrease the risk of BPD, though the mechanisms of action are not clear. Caffeine has been
shown to increase carbon dioxide chemoreceptor responsiveness, increase respiratory
muscle performance and generally increase central nervous system excitability.79–81 In the
Caffeine for Apnea of Prematurity (CAP) trial, the infants randomized to caffeine therapy
had a lower incidence of BPD (36% vs. 47%, adjusted OR 0.64 (0.52–0.78)), as defined by
oxygen need at 36 weeks PMA.82
Sepsis and the systemic inflammatory response
Sepsis and the systemic inflammatory response increase the likelihood of BPD in premature
infants. Several pathogens have been associated with the development of BPD including
Ureaplasma urealyticum, cytomegalovirus, and adenovirus.83–85 The direct role that these
pathogens play in the development of BPD is unclear, but thought to be related to the
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systemic inflammatory response. The inflammatory response in the lung results in
production of pro-inflammatory cytokines, migration of PMNs and changes in vascular
permeability.86,87 The presence of these factors likely causes immediate damage to alveoli
and capillaries, but also may be related to the long-term arrest of alveolarization seen in
infants with BPD.
Predictive models of BPD
In the last decade, researchers have developed predictive models for long-term morbidities,
such as neurodevelopmental impairment. Schmidt et al.88 examined the impact of BPD,
brain injury, and severe ROP on 18-month outcomes and determined that the incidence of
poor long-term outcomes increased with the presence of 1, 2, or all 3 neonatal morbidities..
Tyson et al.89 examined infants in the NRN and determined that exposure to antenatal
corticosteroids, female sex, singleton birth, and higher birth weight (per 100-g increment)
were each associated with reductions in the risk of death and the risk of death or
neurodevelopmental impairment. The authors developed a simple, Web-based predictive
tool (www.nichd.nih.gov/neonatalestimates) that helps clinicians estimate the likelihood that
intensive care will benefit individual infants.
Clinicians, parents, and researchers would benefit from an accurate predictive model of BPD
risk based on readily available clinical information. Prediction scoring systems have been
described for BPD and have included birth-weight, gestational age, sex, PDA, sepsis and
exposure to mechanical ventilation, but until recently, have not been readily available or
adopted. In many of these scoring systems death was not included as a competing outcome
for BPD.90–92 Some included radiographs as part of the scoring system, which introduces
subjectivity and reduces generalizability.93–96 Several used respiratory parameters that are
not readily available to clinicians.97,98 In spite of generally good negative predictive values,
the positive predictive values of these predictive models are low (range 65% to 75%). 93–100
Other significant problems were the absence of a contemporary cohort that included a high
proportion of infants receiving antenatal corticosteroids and surfactant therapy.94 None
examined the risk of BPD based on the NICHD severity based system.
An additional problem with previously reported analyses is a lack of detail regarding the
change in BPD risk with advancing postnatal age.90–92,94 Prior multivariable models
included risk factors identifiable at birth, as well as exposures up to the time of diagnosis of
BPD, but do not include postnatal age. The inclusion of postnatal age allows for the variable
contribution of risk factors over time as potential preventative or therapeutic strategies that
may be employed to decrease the risk of BPD.
Laughon et al. recently developed a predictive model using data from the NICHD NRN
Benchmarking Trial, which is available online at https://neonatal.rti.org.38 This model
incorporates gestational age, birth weight, race and ethnicity, sex, respiratory support and
fractional of inspired oxygen in a parsimonious model, providing estimates of severity of
BPD or death by postnatal day. It is noteworthy that several previously described risk
factors- PDA, NEC, sepsis and postnatal corticosteroids did not significantly improve the
prediction of BPD after adjustment for the other six factors. For example, a white male
infant born at 26 weeks (BW 750g) who at day 7 of life is on CPAP with an oxygen
requirement of 35% has a 19.9% probability of having severe BPD, 34.2% for moderate
BPD, 28.6% for mild BPD and 10.2% for no BPD. An important feature of this model is that
the relative contribution of each predicting factor changes with increasing postnatal age. In
postnatal day 1 and 3 models, gestational age provides the most information, while at later
time points, mechanical ventilation conveys the most predictive information.
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The development of bronchopulmonary dysplasia is the result of the complex interactions
between multiple perinatal and postnatal factors. Although predictive factors for BPD are
easy to identify they are often difficult to modify. Early identification of infants at the
greatest risk of developing BPD through the use of estimators and models may allow a
targeted approach for reducing BPD in the future.
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• Bronchopulmonary dysplasia, also called chronic lung disease, is the most
common serious pulmonary morbidity in premature infants.
• Premature infants with BPD have life-long morbidities including an increased
risk of cerebral palsy and mental retardation.
• The incidence of BPD is inversely related to gestational age and birth weight.
• Prediction of BPD using parsimonious models by postnatal day is now possible.
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Risk of chronic lung disease (or bronchopulmonary dysplasia) among 1340 extremely low
gestational age newborns with 3 patterns of respiratory disease. Reprinted with permission
from the American Academy of Pediatrics from Laughon et al. Pediatrics 2009. 123. 1124–
1131.
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Table 1
NICHD severity-based definition of BPD
Gestational age at
birth
Mild BPD Moderate BPD Severe BPD
<32 weeks Room air at 36 wk PMA or
discharge*
<30% oxygen at 36 wk PMA or
discharge*
≥30% oxygen and/or positive pressure at
36 wk PMA*
≥ 32 weeks Room air by 56 d postnatal age
or discharge*
<30% oxygen at 56 d postnatal age or
discharge*
≥30% oxygen and/or positive pressure at
56 d postnatal age or discharge*
*
All categories require treatment with >21% for at least 28 days, then assessment at PMA/postnatal day or discharge whichever comes first
Adapted from Jobe & Bancalari, American Journal of Respiratory and Critical Care Medicine, 2001.
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